Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Despite the achievement of hematological remission (CR), acute myeloid leukemia (AML) patients with persistence of detectable disease assessed with high sensitivity techniques (multicolor-flow-cytometry, MFC, or PCR-based molecular analysis) show a poor outcome. The aim of our study was to evaluate the prognostic impact of MFC and molecular minimal residual disease (MRD) assessment in a cohort of AML patients who had received a fludarabine-high dose cytarabine containing induction (FLAI) as front-line treatment by identifying optimal time-points (TPs) and MFC and molecular MRD cut-off values.